Application of System Biology to Explore the Association of Neprilysin, Angiotensin-Converting Enzyme 2 (ACE2), and Carbonic Anhydrase (CA) in Pathogenesis of SARS-CoV-2

Reza Zolfaghari Emameh1*, Reza Falak2 and Elham Bahreini3

Abstract

Background: Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) appears with common symptoms including fever, dry cough, and fatigue, as well as some less common symptoms such as loss of taste and smell, diarrhea, skin rashes and discoloration of fingers. COVID-19 patients may also suffer from serious symptoms including shortness of breathing, chest pressure and pain, as well as loss of daily routine habits, pointing out to a severe reduction in the quality of life. COVID-19 has afftected almost all countries, however, the United States contains the highest number of infection (> 1,595,000 cases) and deaths cases (> 95,000 deaths) in the world until May 21, 2020. Finding an influential treatment strategy against COVID-19 can be facilitated through better understanding of the virus pathogenesis and consequently interrupting the biochemical pathways that the virus may play role in human body as the current reservoir of the virus.

Results: In this study, we combined system biology and bioinformatic approaches to define the role of coexpression of angiotensin-converting enzyme 2 (ACE2), neprilysin or membrane metallo-endopeptidase (MME), and carbonic anhydrases (CAs) and their association in the pathogenesis of SARS-CoV-2. The results revealed that ACE2 as the cellular attachment site of SARS-CoV-2, neprilysin, and CAs have a great contribution together in the renin angiotensin system (RAS) and consequently in pathogenesis of SARS-CoV-2 in the vital organs such as respiratory, renal, and blood circulation systems. Any disorder in neprilysin, ACE2, and CAs can lead to increase of CO2 concentration in blood and respiratory acidosis, induction of pulmonary edema and heart and renal failures.

Conclusions: Due to the presence of ACE2-Neprilysin-CA complex in most of vital organs and as a receptor of COVID-19, it is expected that most organs are affected by SARS-CoV-2 such as inflammation and fibrosis of lungs, which may conversely affect their vital functions, temporary or permanently, sometimes leading to death. Therefore, ACE2-Neprilysin-CA complex could be the key factor of pathogenesis of SARS-CoV-2 and may provide us useful information to find better provocative and therapeutic strategies against COVID-19.

(Continued on next page)
Keywords: SARS-CoV-2, COVID-19, Angiotensin-converting enzyme 2 (ACE2), Neprilysin, Carbonic anhydrases (CAs), Renin angiotensin system (RAS), Acute respiratory syndrome, Respiratory acidosis

Background
Since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the worldwide outbreak of coronavirus disease 2019 (COVID-19), the number of infected and death cases have exceeded 4,300,000 and 290,000, respectively until May 21, 2020. Taken together all the observations, world health organization (WHO) declared COVID-19 as a pandemic viral infection based on the prevalence rate and severity of the disease [1, 2] (Table 1).

The COVID-19 patients suffer from several clinical symptoms including fever, dry cough, fatigue, headache, sore throat, loss of taste and smell, aches and pains, diarrhea, skin rashes and/or discoloration of fingers and toes, shortness of breathing, chest pressure and pain, and loss of speech and movement. Since the outbreak of COVID-19 around the world, many academic groups and pharmaceutical companies have focused on developing therapeutic compounds to provide an effective vaccine against COVID-19. The studies revealed that remdesivir [3], combination of lopinavir and ritonavir (weak recommendation) [4], corticosteroids [5], interferon along with combination of lopinavir and ritonavir [4], and immunoglobulin-therapy through transfusion of immune plasma can be the possible therapeutic options for treatment of COVID-19. For COVID-19 prevention, the studies can focus on the results obtained from SARS-CoV vaccine clinical trials such as application of DNA, viral vector, subunit, viral-like particle, inactivated virus, and live-attenuated virus platforms [6].

To achieve an effective treatment, it is necessary to know more about the mechanism of action and pathogenesis of SARS-CoV-2. Four structural proteins including spike (S), membrane (M), nucleocapsid (N), and envelope (E) antigens are the main constituents of SARS-CoV-2 [7]. S protein is a 150 kDa glycoprotein with a N-terminal signal peptide sequence, which is glycosylated at endoplasmic reticulum (ER) [8]. The most abundant structural protein is M protein (25–30 kDa) comprising three transmembrane domains with crucial roles in the virion formation and stabilizing the complexes during the virion assembly through binding of a small glycosylated N-terminal region of M protein to N protein [9]. N protein (50–60 kDa) binds to RNA through N-terminal domain (NTD) and C-terminal domain (CTD), which is induced by phosphorylation of N protein, genomic packaging signal (GPS), replicase-transcriptase complex (RTC), and transcription regulatory signal (TRS).

Table 1 Statistics of worldwide COVID-19 cases until May 21, 2020

| Continent     | Country (top 3 countries for confirmed cases) | Confirmed cases | Deaths | Recovered cases |
|---------------|----------------------------------------------|-----------------|--------|-----------------|
| Asia          | Iran                                         | > 129,000       | > 7250 | > 100,560       |
|               | India                                        | > 113,300       | > 3450 | > 45,900        |
|               | China                                        | > 82,960        | > 4600 | > 78,200        |
| Europe        | Russia                                       | > 317,500       | > 3100 | > 92,600        |
|               | Spain                                        | > 279,500       | > 2700 | > 197,000       |
|               | UK                                           | > 248,300       | > 35700| N/A             |
| North America | United States                                | > 1,595,000     | > 95000| > 371,000       |
|               | Canada                                       | > 80,100        | > 6000 | > 40,800        |
|               | Mexico                                       | > 56,600        | > 6100 | > 38,900        |
| South America | Brazil                                       | > 294,100       | > 19000| > 117,000       |
|               | Peru                                         | > 104,000       | > 3000 | > 42,000        |
|               | Chile                                        | > 53,600        | > 544  | > 22,500        |
| Africa        | South Africa                                 | > 18,000        | > 340  | > 9000          |
|               | Egypt                                        | > 14,200        | > 680  | > 4000          |
|               | Morocco                                      | > 7200          | > 200  | > 4200          |
| Oceania       | Australia                                    | > 7100          | > 100  | > 6500          |
|               | New Zealand                                  | > 1500          | > 20   | > 1450          |
|               | French Polynesia                             | > 60            | 0      | > 60            |
E protein (8–12 kDa) is a transmembrane protein with ion channel activity and major role in assembly and release of virions from the infected cells [11]. Although E protein is not required for replication of the virus, it plays role in pathogenesis of SARS-CoVs.

At the cellular level, the first viral entry step is the binding of the viral trimeric S protein to the human angiotensin converting enzyme 2 (ACE2) receptor [12]. Moreover, CD147 [13], dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN, CD209) [14] and L-SIGN (CD209L) [15] are other entry receptors for SARS-CoV-2. ACE2 is a glycosylated zinc metallopeptidase and a part of the local renin-angiotensin system (RAS). Based on native function of type I membranous endopeptidases in modification of N-terminal region of proteins, ACE2 contains an extracellular N-terminal active site [16]. This enzyme is expressed in most tissues including kidneys, heart, intestine and lungs, and hydrolyze circulating angiotensin molecules. ACE2 counteracts the effects of ACE by converting angiotensin I into Ang-(1-7) and reducing the amount of angiotensin II and balancing the ratio of circulating Ang II/ Ang-(1-7) levels [17, 18]. Elevated Ang II production in the pulmonary system triggers local vascular permeability which may result in lung edema [19, 20]. Moreover, Ang II induces pulmonary vasoconstriction in response to hypoxia. Ang-(1-7) has vasodilator, anti-proliferative, and anti-angiogenic properties, while Ang II is a vasoconstrictor, a mitogenic, and an angiogenic factor [21].

In acute respiratory distress syndrome (ARDS), if the RAS does not help in oxygenation, the general lung injury will result in pulmonary failure. Most probably, in ARDS models, ACE2 knockout will result in more severe symptoms, while overexpression might protect the lung from further injury [22].

As mentioned, ACE2 is also exploited by SARS-CoV-2 as the entry receptor. Due to the high expression of ACE2 in the lungs, intestines, respiratory tract, and also enteric system, these organs are the main sites of SARS-CoV-2 infections that are manifested by symptoms like fever, cough, pneumonia, shortness or difficulty of breathing, anorexia, sometimes diarrhea, and abdominal pain [23]. Therefore, it is considered that coronavirus infection can be controlled by blocking ACE2 and preventing the virus from binding to the cells [12]. Despite the mentioned assumption, some animal studies have shown that an increase in Ang-(1-7) has a protective effect against virus-induced lung injury via the vasodilatory effects [22, 24]. It seems that, persistent angiotensin II activity may be partly responsible for organ injury in COVID-19 [19].

Due to insufficient information on the infectious mechanism of the virus, most studies have focused on preventing the first stage of viral infection by reducing ACE2, but ACE2 knock down leads to high activation of local RAS and increased tissue injury, hypertension and renal and cardiovascular complications. Therefore, the evaluation of the efficacy of recently designed vaccines for COVID-19 requires appropriate animal models such as ACE2-transgenic and ACE2-knockout mice [25].

Although, ACE2 is the major producer of Ang-(1-7), there are other enzymes such as nephrisyn, prolyl-endopeptidase (PEP) and prolyl-carboxy-peptidase (PCP) that can produce Ang-(1-7) from Ang I [26, 27]. Among the aforementioned enzymes, high expression levels of nephrisyn have been detected in the lung, especially in pulmonary epithelial cells [21]. This zinc-dependent MME is expressed in a wide variety of tissues and in addition to hydrolyzing the Ang I to Ang-(1-7), it is involved in converting several endogenous propeptides into their functional form. According to evidence, nephrisyn regulates lung tissue responses to broncho-constriction inducing peptides [21, 28]. Thus, upregulation of nephrisyn can be considered as a compensatory mechanism to control the concentration of Ang-(1-7) levels during COVID-19 treatment.

Airway management and hyperbaric oxygen therapy (HBOT) is the main supportive treatments for patients with severe COVID-19 as well as severe pneumonia [29]. Previous studies have revealed that the levels of both angiotensinogen and Ang II receptors increases in hypoxic conditions [30, 31]. Consequently, hypoxic conditions in COVID-19 will increase Ang II concentration through downregulation of ACE2 [32, 33]. Lungs and alveoli as the main parts of lower respiratory system have the main role in the oxygen (O2) exchange with carbon dioxide (CO2) at the molecular level; CA plays a crucial function in this respiratory exchange [34, 35]. CA as another Zn-metalloenzyme catalyzes the hydration of CO2 into carbonic acid and vice versa [36–38]. One of the adaptive responses to hypoxia includes the increased expression and functional activation of CA IX [39]. In this study, we applied a system biology approach to explore the association of ACE2, nephrisyn, and CA, which may ameliorate COVID-19 symptoms in the lungs alveoli.

Methods

Identification of Coexpression of ACE2, Nephrisyn, and CA

To identify role of coexpression of ACE2, nephrisyn, and CA in COVID-19 pathogenesis, we used COXPRESdb v7 (https://coxpresdb.jp/) [40]. In this database, we applied the CoexViwer algorithm to identify and draw the coexpression of genes, which are linked to activation of nephrisyn. This database facilitates the visualization of the multiple gene coexpression information derived from defined animals which were examined with a variety of transcriptomics technologies.

Identification of the Association of Nephrisyn and ACE2

To identify the association of nephrisyn and ACE2, we employed KEGG (Kyoto Encyclopedia of Genes and
Genomes) PATHWAY database [41]. This database represents the information on the reactions, relation networks, and molecular interactions of the molecules.

**Identification of Organ Localization of ACE2, Neprilysin, and CA**

To identify the organ localization of ACE2, neprilysin, and CA, we used THE HUMAN PROTEIN ATLAS online program (https://www.proteinatlas.org/) [42]. This program shows the map of the localization of human proteins in cells, organs, and tissues through application of various system biology, proteomics, and transcriptomics technologies.

**Results**

**Identification of Coexpression of ACE2, Neprilysin, and CA**

The coexpression study revealed that ACE2, neprilysin, and CA are codominantly expressed in the local RAS. The analysis showed that at least 22 genes were coexpressed in the local RAS, which can be linked to COVID-19. This association can be a direct or an indirect coexpression effect; so lack of function of a protein as the consequence of COVID-19 infection may induce the expression or activity of another protein in a different pathway (Fig. 1) (Table 2).

**Identification of Association of Neprilysin and ACE2**

The KEGG PATHWAY defined that neprilysin and ACE2 have association in the RAS. In this system, via two individual biochemical procedures, neprilysin converts Ang I and Ang-(1-9) to Ang-(1-7). In addition, in the RAS, ACE2 facilitates three individual biochemical procedures including conversion of Ang I to Ang-(1-9) as the substrate of neprilysin, Ang II to Ang-(1-7), and Ang A to alamandine which binds to Mas-related G
protein-coupled receptor (MrgprD) to perform the vasodilatory action (Fig. 2).

**Identification of Organ Localization of ACE2, Neprilysin, and CA**

Our analysis based on the data obtained from THE HUMAN PROTEIN ATLAS revealed that neprilysin and ACE2 are highly expressed in the digestive, renal, respiratory, and reproductive systems. The expression pattern of CA in the atlas has shown that this protein is expressed in all human organs. These overlaps in the organ localization of ACE2, neprilysin, and CA demonstrate the possible association of these proteins as a complex in COVID-19 infections through overexpression or down regulation of coding genes expression (Fig. 3).

**Discussion**

The successful computational methodologies were employed previously to design viral vaccines against influenza A, hepatitis A, HIV-1, dengue, and West Nile viruses so a new era was considered in the vaccine

---

**Table 2 Genes directly connected with neprilysin on the coexpression network**

| Locus  | Function       | Entrez Gene ID |
|--------|----------------|----------------|
| CA VB  | carbonic anhydrase SB | 302,669       |
| ACE2   | angiotensin-converting enzyme 2 | 302,668       |

**Fig. 2** Association of neprilysin or MME and ACE2. ACE2 is crucial in conversion of angiotensin I to Ang-(1-9) angiotensin II to Ang-(1-7), and angiotensin A (AngA) to alamandine. In addition, neprilysin or MME is essential in conversion of angiotensin I to Ang-(1-7) and Ang-(1-9) to angiotensin Ang-(1-7)
The bioinformatics analysis reveals the moderate coexpression of ACE2, neprilysin, and CA genes in the human body. As soon as SARS-CoV-2 is entered into the human oral cavity via direct contact or sneezing and cough droplets of a COVID-19 patient, the virus S protein can be attached to the ACE2, the main host cell receptor of SARS-CoV-2 expressed by epithelial cells of
different sites of the oral cavity [47, 48]. Single-cell transcriptome study revealed that the expression rate of ACE2 in the tongue tissue is higher than buccal and gingival tissues [49]. Therefore, primarily SARS-CoV-2 multiplicities in the human mucosa of the oral cavity and consequently a high number of viruses are transmitted to the secondary organ targets expressing ACE2. For this reason, some have claimed drinking water could be a safe way against SARS-CoV-2 which wash the virus into the stomach where acid will inactivate it.

Single-cell sequencing (scRNA-Seq) has shown a high expression rate for ACE2 in type II alveolar (AT2) cells of lung [50], oral cavity epithelial cells [51], upper esophagus [14] and cholangiocytes [52]. A reduction in ACE2 levels due to internalizing by attached SARS-CoV-2 leads to increase in Ang II and consequently vasoconstriction in the lung [53]. Such condition causes respiratory disorders and insufficient air conditioning in alveoli which stimulates lung to upregulate ACE2 expression [54]. According to bioinformatics prediction of the coexpression of ACE2, nephrilysin, and CA; an increase in nephrilysin and upregulation of CA may attenuate the severity of disease and compensate the alveolar ventilation [55–59]. The elevated Ang II in lung tissue following a decrease in ACE2 by COVID-19 binding may increase the comorbidities, most likely due to inducing local and systemic inflammation. The proinflammatory effects of Ang II are mediated by increased oxidative stress. Elevated serum concentrations of C-reactive protein (CRP) is an indicator of systemic inflammation in such conditions [60].

ACE2 also is expressed in other tissues including proximal tubular cells of kidney [61], colon and ileum of the digestive system [62], urothelial cells of the gallbladder [49], and liver, pancreas and heart myocytes [63], which can justify COVID-19 infection side effects. ACE2 is also expressed in lymphocytes and following infection with the virus, their population decreases and the immune system weakens [13].

Also, different isoenzymes of CA have a high rate of expression in various tissues with critical biochemical functions in the pH homeostasis and alveolar O$_2$-CO$_2$ exchange [64]. After the inhalation, the oxygen is entered to alveoli with higher pressure than blood capillaries and delivered to hemoglobin in red blood cells (RBCs) [65]. Then, H$_2$CO$_3$ is catalyzed to CO$_2$ and water molecule by CA II of RBCs. In the acute COVID-19, following the destructive effects of virus on the pulmonary cells, the O$_2$-CO$_2$ exchange rate is impaired, leading to respiratory acidosis and shifting the pH of blood to acidic state and also increasing the concentration of blood CO$_2$ [66]. Subsequently, the kidney proximal tubular cells increase reabsorption of HCO$_3^-$ leading to acid and ammonium excretion [67]. Then, H$^+$ of the tubular fluid is combined with HCO$_3^-$ producing H$_2$CO$_3$, which is catalyzed to H$_2$O and CO$_2$ by CAs localized in kidney tissue [68]. Hence, as the consequence of infection of various cells including pulmonary cells of lungs, myocytes of heart, proximal tubular cells of kidney, and other ACE2-expressing cells (which mainly express CAs) with SARS-CoV-2 and reducing the ability of CO$_2$ exhalation, the concentration of blood CO$_2$ is elevated so even the lungs alveoli became unable in O$_2$-CO$_2$ exchange with pulmonary artery and vein through the CA enzymatic reaction [69]. The respiratory acidosis is associated with weakness of the respiratory muscles, arrhythmias, hypotension, myocardial depression, and decreasing in renal blood flow [66]. As the immunological aspect, the respiratory acidosis induces apoptosis and release of proinflammatory cytokines following RAS activation and raising the expression level of angiotensinogen by leukocytes [70]. Finally, the respiratory acidosis can lead to pulmonary edema, severe hypoxia as well as heart and renal failures [66]. Regarding to coexpression analyses results and referring to lack of sufficient information related to human CA VB, we couldn’t find the reason of the coexpression prediction of nephrilysin and ACE2 with CA VB, which needs further experiments in future.

Conclusions

Overall, due to high expression rate of ACE2 in the human organs and presence of a potential association with nephrilysin in RAS and CAs, SARS-CoV-2 could be considered as an aggressive pathogen to all human organs which express ACE2. Therefore, this pathologic association (ACE2-Nephrilysin-CA) complex can present valuable physiologic information to clinicians to innovate more influential treatment protocols against COVID-19.

Abbreviations

ACE2: Angiotensin-converting enzyme 2; ARDS: Acute respiratory distress syndrome; HCO$_3$$: Bicarbonate; H$_2$CO$_3$: Carbonic acid; CA: Carbonic anhydrase; COVID-19: Coronavirus disease 2019; CO$_2$: Carbon dioxide; CRP: C-reactive protein; DC-SIGN: Dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin; E: Envelope; HBOT: Hyperbaric oxygen therapy; HIV: Human immunodeficiency virus; KEGG: Kyoto Encyclopedia of Genes and Genomes; M: Membrane; MME: Membrane metalloendopeptidase; MrgprD: Mas-related G protein-coupled receptor; N: Nucleocapsid; O$_2$: Oxygen; RAS: Renin angiotensin system; RBC: Red blood cell; S: Spike; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2

Acknowledgements

We thank the Deputy of Research and COVID-19 National Committee at the National Institute of Genetic Engineering and Biotechnology (NIGEB) of the Islamic Republic of Iran for preparing the condition to perform this study. No funding organizations had any role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; nor in the decision to publish the results.

Authors’ Contributions

All authors participated in the design of the study. RZE designed and carried out the search and data mining related to the coexpression of ACE2-Nephrilysin-CA complex as well as databases for this study. RF performed the system biology and bioinformatic studies. RF participated in the immunological and EB participated in the biochemical studies and further
8. Belouzard S, Millet JK, Licitra BN, Whittaker GR. Mechanisms of coronavirus

7. McBride R, van Zyl M, Fielding BC. The coronavirus nucleocapsid is a

3. Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al.

2. Zolfaghari Emameh R, Nosrati H, Taheri RA. Combination of biodata mining

1. Mahase E. Covid-19: WHO declares pandemic because of

References

1. Mahase E. Covid-19: WHO declares pandemic because of "alarming levels" of spread, severity, and inaction. BMJ. 2020;368:m1036.

2. Zolfaghari Emameh R, Nosrati H, Taheri RA. Combination of biodata mining and computational modelling in identification and characterization of ORF1ab polyprotein of SARS-CoV-2 isolated from Oronasopharynx of an Iranian patient. Biol Proced Online. 2020;22:28.

3. Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate use of Remdesivir for patients with severe Covid-19. N Engl J Med. 2020;383(4):252–5.

4. Jin YH, Ci J, Chiung ZS, Cheng H, Deng T, Fan YP, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res. 2020;7(1):4.

5. Russell CD, Millett JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395(10223):473–5.

6. Promptcheara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol. 2020;38(1):1–9.

7. McBride R, van Zyl M, Fielding BC. The coronavirus nucleocapsid is a multifunctional protein. Viruses. 2014;6(8):2991–3018.

8. Belouzard S, Millet JK, Licitra BN, Whittaker GR. Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses. 2012;4(6):1011–33.

9. Arndt AL, Larson BJ, Hogue BG. A conserved domain in the coronavirus membrane protein tail is important for virus assembly. J Virol. 2010;84(21):11418–28.

10. Zuniga S, Cruz JL, Solà I, Mateos-Gomez PA, Palacios L, Juanes L. Coronavirus nucleocapsid protein facilitates template switching and is required for efficient transcription. J Virol. 2010;84(4):2169–75.

11. Verdia-Baguena C, Nieto-Torres JL, Alcaraz A, DeDiego ML, Torres J, Aguillera VM, et al. Coronavirus E protein forms ion channels with functional and structurally-involved membrane lipids. Virology. 2012;432(2):485–94.

12. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020; 367(6485):1444–8.

13. Wang X, Xu W, Hu G, Xia S, Sun Z, Liu Z, et al. SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion. Cell Mol Immunol. 2020;1–3.

14. Qi F, Qian S, Zhang S, Zhang Z. Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses. Biochem Biophys Res Commun. 2020;526(1):135–40.

15. Jeffers SA, Tusell SM, Gillimm-Ross L, Hemmilia EM, Achenbach JE, Babcock GJ, et al. CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci U S A. 2004;101(44):15748–53.

16. Vanland S, Osberg C, Arnesen T. N-terminal modifications of cellular proteins: the enzymes involved, their substrate specificities and biological effects. Proteomics. 2015;15(14):2385–401.

17. Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev. 2006;86(3):747–803.

18. Gandhi C, Uhal BD. Roles of the angiotensin system in neonatal lung injury and disease. JSM Atheroscler. 2016;3(3):1014.

19. Deng Z, Wang DX, Deng W, Li CY, Tong J. The effect of endogenous angiotensin II on alveolar fluid clearance in rats with acute lung injury. Can Respir J. 2012;19(5):311–8.

20. Imay Y, Kuba K, Penninger JM. The renin-angiotensin system in acute respiratory distress syndrome. Drug Discov Today Dis Mech. 2006;3(2):225–9.

21. Gallagher PE, Cook K, Soto-Pantoja D, Menon J, Tallant EA. Angiotensin peptides and lung cancer. Curr Cancer Drug Targets. 2011;11(4):394–404.

22. Imai Y, Kuba K, Penninger JM. The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice. Exp Physiol. 2008; 93(5):543–8.

23. Adhikari SP, Meng S, Wu YJ, Mao YP, Ye RX, Wang GZ, et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect Dis Poverty. 2020;9(1):29.

24. Ja H. Pulmonary angiotensin-converting enzyme 2 (ACE2) and inflammatory lung disease. Shock (Augusta, Ga). 2016;46(3):239–48.

25. Imay Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436(7047):112–6.

26. Grobe N, Weir NM, Leiva O, Ong FS, Bernstein KE, Schmaier AH, et al. Identification of prolyl carboxypeptidase as an alternative enzyme for processing of reninal angiotensin II using mass spectrometry. Am J Phys Cell Phys. 2013;304(10):C945–53.

27. Domenig O, Manzel A, Grobe N, Konigshausen E, Kaltenecce CC, Kovarik JJ, et al. Neprilysin is a mediator of alternative renin-angiotensin-system activation in the murine and human kidney. Sci Rep. 2016;6:33678.

28. Wick MJ, Buesing EJ, Weilungs CA, Loomis ZL, Cool CD, Zamora MR, et al. Decreased nephrilysin and pulmonary vascular remodeling in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011;183(3):330–40.

29. Geier MR, Geier DA. Respiratory conditions in coronavirus disease 2019 (COVID-19): important considerations regarding novel treatment strategies to reduce mortality. Med Hypotheses. 2020;140:109760.

30. Hubloue I, Rondelet B, Kerbaf B, Biaret D, Milani GM, Staroukine M, et al. Endogenous angiotensin II in the regulation of hypoxic pulmonary vasoconstriction in anesthetized dogs. Cirt Care. 2004;8(4):R163–71.

31. Zhao L, al-Tubuly R, Sekhia R, Oyew AA, Nunez DJ, Willlkins MR. Angiotensin ii receptor expression and inhibition in the chronically hypoxic rat lung. Br J Pharmacol. 1996;119(6):1217–22.

32. Mohamed TL, Nguyen HT, Abdul-Hafez A, Dang VX, Dang MT, Gewolb IH, et al. Prior hypoxia prevents downregulation of ACE-2 by hypoxia in fetal human lung fibroblasts. Exp Lung Res. 2016;42(5):211–30.

33. Varagic J, Ahmad S, Nagata S, Ferrario CM. ACE2: angiotensin II/angiotensin-1(7)-converting enzyme activity in cardiac and renal injury. Curr Hypertens Rep. 2014;16(3):420.

34. Farhi LE, Plewes JL, Olszowka AJ. Lung carbonate dehydratase (cdeh) gene expression in human and rat lung. Pulm Pharmacol Ther. 1996;9(4):269–75.

35. Grobe N, Weir NM, Leiva O, Ong FS, Bernstein KE, Schmaier AH, et al. Identification of prolyl carboxypeptidase as an alternative enzyme for processing of reninal angiotensin II using mass spectrometry. Am J Phys Cell Phys. 2013;304(10):C945–53.

36. Zolfaghari Emameh R, Barker HR, Syrjanen L, Urbanski L, Supuran CT, Parkkila S. S. Ascaris lumbricoides beta carbonic anhydrase: a potential target enzyme for treatment of ascariasis. Parasit Vectors. 2015;8:479.

37. Zolfaghari Emameh R, Kuuslahti M, Vullo D, Barker HR, Supuran CT, Parkkila S. Beta carbonic anhydrase sequences from vertebrates. BMC Genomics. 2020;21(1):352.
